I'm going to move on to organics, Ms. McMahon.
One thing we've had a lot of testimony on before this committee, not at this sitting but before, when we looked at the biotech sector—and I know Mr. Valeriote was working pretty hard on this—is trying to figure out a way that organics and the biotech sector and GMO sector can survive side by side. One question that keeps reoccurring concerns low-level presence and the acceptability of a reasonable amount of low-level presence. Have you in your sector talked about this, and have you looked at where we need to be with it? Is there a compromise to be had here?